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Disruption of hepatocyte growth hormone (GH) signaling
through disruption of Jak2 (JAK2L) leads to fatty liver.
Previously, we demonstrated that development of fatty
liver depends on adipocyte GH signaling. We sought to
determine the individual roles of hepatocyte and adipo-
cyte Jak2 on whole-body and tissue insulin sensitivity
and liver metabolism. On chow, JAK2L mice had hepatic
steatosis and severe whole-body and hepatic insulin
resistance. However, concomitant deletion of Jak2 in hep-
atocytes and adipocytes (JAK2LA) completely normal-
ized insulin sensitivity while reducing liver lipid content.
On high-fat diet, JAK2L mice had hepatic steatosis and
insulin resistance despite protection from diet-induced
obesity. JAK2LA mice had higher liver lipid content and
no protection from obesity but retained exquisite he-
patic insulin sensitivity. AKT activity was selectively
attenuated in JAK2L adipose tissue, whereas hepatic
insulin signaling remained intact despite profound he-
patic insulin resistance. Therefore, JAK2 in adipose tis-
sue is epistatic to liver with regard to insulin sensitivity
and responsiveness, despite fatty liver and obesity.
However, hepatocyte autonomous JAK2 signaling reg-
ulates liver lipid deposition under conditions of excess
dietary fat. This work demonstrates how various tis-
sues integrate JAK2 signals to regulate insulin/glucose
and lipid metabolism.
The regulation of glucose metabolism by the anterior pituitary
gland was described nearly 100 years ago. Hypophysectomy
sensitizes animals to the hypoglycemic effects of insulin,
whereas conversely, hypophyseal extracts confer potent di-
abetogenic activity (1). The major anterior pituitary-derived
diabetogenic factor was determined to be growth hormone
(GH) (2). However, treatment with recombinant GH has
ostensible beneficial effects, such as reductions in fat mass
(3), and patients with GH deficiency (GHD) or insensitivity
(GHI) may be prone to nonalcoholic steatohepatitis (NASH)
and fatty liver (4), complicating the discussion around the
potential metabolic benefits of inhibiting GH action.
GH signals through the GH receptor (GHR), JAK2, and
then STAT5 to induce Igf1. Hepatocyte GH signaling con-
trols levels of circulating IGF-I, which in turn feedback
inhibits GH secretion in the hypothalamus/pituitary gland
(5). Therefore, when hepatocyte GH signaling is inhibited at
the level of the GHR, JAK2, or STAT5, circulating GH levels
increase and can hyperstimulate other GH responses, such
as adipose tissue lipolysis.
Although GH is unquestionably a potent mediator of
adipose tissue lipolysis (6), whether GH modulates lipolysis
directly or indirectly remains unknown. We have shown
that GH promotes lipolysis indirectly through inhibitory
effects on insulin action and that short-term GH administration
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induces insulin resistance (6,7). This finding puts forth
a mechanistic explanation of the Houssay effect wherein
high levels of circulating GH promote adipocyte lipolysis,
the by-products of which drive hepatic insulin resistance
(8). Data supporting this hypothesis show that inhibition
of lipolysis in patients with acromegaly normalizes hepatic
insulin sensitivity (9,10). Therefore, adipose tissue regulates
many of the biological consequences of GH signaling, including
liver metabolism.
Although hepatocyte-specific GHI through deletion of
Ghr (11), STAT5 (12), or Jak2 (5,13) leads to fatty liver,
precisely how GH leads liver lipid deposition remains unclear.
GH has been shown to be an inhibitor of hepatic de novo
lipogenesis (DNL) because induction of hepatocyte-specific,
adult-onset GHD increases DNL (14). However, we did not
observe differences in DNL in mice with congenital hepatocyte-
specific GHI (JAK2L) (6). Furthermore, we have demon-
strated that concomitant disruption of hepatocyte Cd36
largely prevents fatty liver in JAK2L mice, suggesting that
hepatic GH signaling–mediated regulation of fatty acid up-
take is important in determining liver lipid content (15). Of
note, although Cd36 disruption restored normal liver lipid
levels, reversal of the fatty liver phenotype did not restore
insulin sensitivity, suggesting that a tissue other than liver
likely governs hepatic insulin sensitivity. Consistent with this
finding, genetic disruption of GH secretion or concomitant
deletion of adipocyte Jak2 prevents fatty liver development
in mice that cannot transduce hepatic GH signals (5,6).
Insulin signaling is transduced through insulin receptor
tyrosine kinase engagement and autophosphorylation followed
by a kinase cascade centered on AKT, an obligate regulator
of insulin-mediated physiology (16). AKT activation is asso-
ciated with phosphorylation of two key residues, threonine
308 and serine 473, by PDK1 and mTORC2 kinases, respec-
tively (17). Activated AKT then phosphorylates a number of
targets, including PRAS40/AKT1S1, an mTORC1 inhibitor
and regulator of glucose homeostasis (18). Insulin stimulates
phosphorylation of PRAS40 on threonine 246 through AKT,
relieving PRAS40-mediated inhibition of mTORC1 (19). The
role of cell-autonomous insulin signaling in the regulation
of hepatic insulin sensitivity is debated, with some studies
favoring a dominant role of insulin action in liver (20) and
others finding hepatic insulin signaling to be dispensable (21).
In the current study, we use hyperinsulinemic-euglycemic
clamps and targeted lipidomics to describe the respective
metabolic roles of liver and adipose JAK2. In chow-fed mice,
those with hepatocyte GHI (JAK2L) were insulin resistant,
whereas combined hepatocyte-adipocyte GHI (JAK2LA) re-
stored insulin sensitivity. Insulin resistance in JAK2L mice
correlated with high levels of fed circulating fatty acids and
liver triacylglycerol (TAG) and diacylglycerol (DAG), all of
which were reduced dramatically in insulin-sensitive JAK2LA
mice. After a high-fat diet (HFD), hepatic insulin sensitivity
further deteriorated in JAK2L mice, whereas JAK2LA mice
retained exquisite hepatic and whole-body insulin sensitivity
despite developing profound fatty liver. Although no defects
in insulin-stimulated AKT phosphorylation were observed in
the insulin resistant state, AKT activity, as measured by
PRAS40 threonine 246 phosphorylation, was selectively atten-
uated in JAK2L adipose tissue. Of note, hepatic insulin
resistance in JAK2L mice was not associated with reduced
liver insulin signaling under clamped conditions. Therefore,
adipocyte JAK2 appears to be epistatic to hepatocyte JAK2
with regard to insulin sensitivity and fatty liver in chow-fed
animals. However, after HFD, loss of adipocyte Jak2 is in-
sufficient to prevent fatty liver in mice with hepatocyte
GHI. Finally, disruption of JAK2 in adipose tissue is sufficient
to maintain remarkable hepatic insulin sensitivity in the face
of altered hepatic lipid metabolism.
RESEARCH DESIGN AND METHODS
Animals and Diets
Production of albumin:CRE;Jak2lox/lox (JAK2L) and compound
albumin:CRE;Jak2lox/lox/adiponectin:CRE;Jak2lox/lox (JAK2LA)
mice were previously described (6). Jak2lox/lox mice (22)
were backcrossed onto the C57BL/6 background for at least
nine generations and used as the control (CON). For chow
studies, mice were fed PicoLab Mouse Diet 20 (LabDiet
#5058; 23% of calories from protein, 22% from fat, and
55% from carbohydrate), and for HFD studies, mice were
fed Research Diets D12492 (20% of calories from protein,
60% from fat, and 20% from carbohydrate).
Animal Studies and Sample Collection
Six-week-old CON, JAK2L, and JAK2LA mice were fed an
HFD or were maintained on chow for 10 weeks. Total fat
mass was determined by DEXA on isoflurane-anesthetized
mice by using a Lunar PIXImus2 densitometer (GE Health-
care). Blood glucose and serum insulin levels were determined
after a 16-h overnight fast by hand-held glucometer (Bayer)
and ELISA (ALPCO), respectively. For insulin tolerance testing
(ITT), mice were fasted for 4 h (0900–1300 h) followed by
intraperitoneal injection of 1 unit/kg insulin (Novolin; Novo
Nordisk, Bagsværd, Denmark). Blood glucose levels were
determined by tail prick with a hand-held glucometer at
the times indicated. Free fatty acid (FFA) levels were deter-
mined by using an enzyme-linked colormetric assay (Wako).
For final tissue collection, samples were collected from ad
libitum fed mice starting at 1000 h by using standard sterile
techniques. Tissue was harvested and immediately snap frozen
in liquid nitrogen or suspended in 4% paraformaldehyde for
histological analysis. Blood was collected from the retroorbital
sinus and allowed to clot before centrifugation at 10,000g for
10 min at 4°C for serum separation. Serum was stored
at280°C before analyses. Clinical chemistry was performed
by the University of California, Davis, Comparative Pathol-
ogy Laboratory.
Hyperinsulinemic-Euglycemic Clamp Studies
Clamp studies were performed according to recommendations
of the National Institutes of Health–funded Mouse Metabolic
Phenotyping Consortium and as previously described (23,24).
Briefly, mice recovered 1 week after receiving surgery to
implant an indwelling jugular vein catheter before clamp
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studies. Mice were fasted overnight and received a basal in-
fusion of 3-3H-glucose conjugated to BSA to determine fast-
ing glucose. A primed/continuous infusion of insulin and
3-3H-glucose was administered alongside a variable infusion
of 20% dextrose to maintain euglycemia during the hyper-
insulinemic portion of the study. A 10-mCi bolus injection
of 14C-2-deoxyglucose was given at 90 min to determine
tissue-specific glucose uptake, which was calculated from the
area under the curve of 14C-2-deoxyglucose detected in
plasma and the tissue content of 14C-2-deoxyglucose-6-
phosphate. Blood was collected by tail massage at set intervals,
and glucose levels were measured by glucose oxidase method.
Insulin infusion rates were as follows: chow 2.5 mU $ kg21 $
min21 and HFD 4.0 mU $ kg21 $ min21. Glucose turnover
was determined as the ratio of the 3-3H-glucose infusion
rates (GIRs) to the specific activity corrected to the contri-
bution of the infusion rate during the last 40 min of the
hyperinsulinemic infusion. Calculation of endogenous glucose
production (EGP) and tissue-specific glucose uptake were de-
scribed previously (24). For chow studies, mice were ;16
weeks of age, and HFD study mice were age-matched to
chow study mice and fed an HFD for 4 weeks before clamps.
Lipidomics
Liver lipidomics and total hepatic triglyceride (TG) analyses
were carried out exactly as previously described (15).
Quantitative PCR
Quantitative PCR and analysis for liver Cd36 was per-
formed exactly as previously described (15).
Western Blots
Liver, gastrocnemius, and epididymal adipose depots were
excised from HFD-fed mice at the end of hyperinsulinemic-
euglycemic clamps and flash frozen. Tissues were homogenized
in a precooled bead mill (Retsch MM400) in radioimmuno-
precipitation assay buffer (50 mmol/L Tris, 150 mmol/L NaCl,
1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, pH
8.0) with Halt Protease and Phosphatase Inhibitor Cocktail
(78440; Thermo Fisher Scientific) for 2min at 30 oscillations/s.
Samples were placed on a tube rotator for 30 min at 4°C and
then centrifuged at 10,000g for 10 min to remove the
nuclear pellet. Immunoblots were performed with 10 mg
total protein on 15-well, 4–12% Bolt Bis-Tris Plus Gels
(Thermo Fisher Scientific). Membranes were stained with
REVERT Total Protein Stain (LiCor) for normalization pur-
poses and incubated overnight with antibodies from Cell
Signaling Technology: pan-AKT (#2920), pSer473-AKT
(#4060), PRAS40 (#2610), and pThr246-PRAS40 (#2997).
Digital images were quantified by using LiCor Image Studio
version 5.2 for Western blot analysis. Each individual mem-
brane was normalized to the REVERT Total Protein Stain, and
the ratio of phosphorylated to total protein was calculated.
Study Approval
All animal studies were approved by institutional animal
care and use committees at the University of California,
San Francisco; University of Pittsburgh; and Yale University.
Statistics and Graphics
All statistical tests and figures were performed with GraphPad
Prism version 6.0 software.
RESULTS
Adipocyte JAK2 Signaling Mediates Insulin Sensitivity
in Mice With Hepatocyte-Specific GHI
Chow-fed JAK2L and JAK2LA mice weighed less than CON
mice (Fig. 1A), whereas JAK2LA mice had increased total fat
mass (Fig. 1B) and percent fat mass as per total body weight
versus CON and JAK2L mice (Fig. 1C). Therefore, concom-
itant loss of adipocyte Jak2 on the JAK2L background,
similar to adipocyte-only Jak2 deletion (7), promoted adi-
posity. The increased fat mass occurred in both visceral
(Fig. 1D) and subcutaneous (Fig. 1E) depots. Fed JAK2L
mice had increased plasma FFAs that were reduced by con-
comitant deletion of adipocyte Jak2 (Fig. 1F). There was
both fasting hyperglycemia (Fig. 1G) and hyperinsulinemia
(Fig. 1H) in JAK2L mice that, as with fed FFA levels, were
normalized in JAK2LA animals. Thus, JAK2L mice have
insulin resistance that is normalized by disruption of
adipocyte Jak2. Indeed, ITTs revealed overt insulin resis-
tance in JAK2L mice, whereas JAK2LA mice were identical
to CON mice.
Chow-Fed JAK2L Mice Have Profound Hepatic and
Whole-Body Insulin Resistance, Which Are Normalized
in JAK2LA Mice
To definitively determine tissue-specific insulin sensitivity,
hyperinsulinemic-euglycemic clamps were performed. No
difference in clamped plasma insulin levels were found between
the groups during the experiment (Supplementary Fig. 1A),
and plasma glucose levels were matched during steady-state
or the last 40 min of the clamp at ;120 mg/dL (Fig. 2A).
Compared to controls, JAK2L mice required a lower GIR to
maintain euglycemia, whereas the JAK2LA cohort did not
differ from CON mice (Fig. 2B and C), confirming normal-
ization of whole-body insulin sensitivity. Consistent with
fasting hyperglycemia (Fig. 1G), basal EGP was increased
in JAK2L animals (Fig. 2D). Furthermore, clamped JAK2L
mice were completely resistant to insulin-mediated reduc-
tions in EGP (Fig. 2E and F), demonstrating profound he-
patic insulin resistance. Hepatic insulin sensitivity was
restored to CON levels in JAK2LA mice (Fig. 2E and F).
Whole-body glucose disposal was reduced in JAK2L but not
JAK2LA mice (Fig. 2G). Skeletal muscle glucose uptake did
not differ statistically by genotype (Fig. 2H), whereas adi-
pose tissue glucose uptake was reduced in both JAK2L and
JAK2LA animals (Fig. 2I). Therefore, disruption of adipo-
cyte Jak2 normalizes whole-body and hepatic insulin sensi-
tivity in mice with hepatocyte-specific GHI.
Reductions in adipocyte lipolysis and plasma FFA have
been shown to be major regulators of insulin-mediated
suppression of hepatic glucose output (8). Therefore, we
measured plasma FFA levels in awake and unanesthetized
clamped CON, JAK2L, and JAK2LA mice. Overnight fasted,
basal FFA levels were reduced in JAK2LA plasma (Fig. 2J).
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After insulin infusion, plasma FFA in CONmice was suppressed
by ;60%, whereas FFA levels were reduced by ;25% in
JAK2L and JAK2LAmice (Fig. 2K and L). Therefore, although
the impaired suppression of lipolysis in the JAK2L mice and
concomitant hepatic insulin resistance was consistent with
a regulatory role of lipolysis on hepatic glucose production,
this effect was not apparent in JAK2LA mice. In addition,
differences in absolute levels of plasma FFA levels did not
correlate with hepatic insulin sensitivity in clamped JAK2L
and JAK2LA mice.
Adipocyte Jak2 Governs Hepatic Lipid Content in
Chow-Fed JAK2L Mice
We previously determined that JAK2Lmice develop fatty liver on
a chow diet, and this is improved in compound JAK2LA animals
(6). To determine the hepatic lipid composition in these
groups, we performed comprehensive targeted liver lipido-
mics. Most TAG (Fig. 3A) and DAG (Fig. 3B) species were
elevated in JAK2L livers compared with CON, and these
were partially restored in JAK2LA livers. Total hepatic cho-
lesterol ester (CE) levels did not differ among the groups,
although a clear shift was observed away from longer-chain,
unsaturated CE in JAK2L and JAK2LA livers (Fig. 3C). Most
species of hepatic ceramide (CER) levels were increased in
JAK2LA versus CON and JAK2L mice (Fig. 3D). These data
support a potential role for reductions in hepatic TAG and
DAG content in mediating the normalized hepatic insulin
sensitivity seen in JAK2LA mice.
JAK2LA Mice Maintain Exquisite Hepatic Insulin
Sensitivity After HFD
The results from the normal chow-fed cohort strongly suggest
that the profound whole-body and hepatic insulin resistance
observed in JAK2L mice depended on the marked increase in
liver lipid content. To explore this further, we next challenged
mice with an HFD. JAK2L mice were resistant to HFD-induced
obesity (Supplementary Fig. 1B), whereas no difference was
found in body weight or adiposity between CON and
JAK2LA mice (Fig. 4A–C). JAK2L animals had reduced vis-
ceral (Fig. 4D) and subcutaneous (Fig. 4E) adipose mass (vs.
CON), whereas a selective expansion of the inguinal sub-
cutaneous depot was observed in JAK2LA animals versus
CON (Fig. 4D and E). Ad libitum fed FFA levels did not
differ by genotype in HFD-fed mice (Fig. 4F). As seen in
Figure 1—Loss of adipocyte Jak2 normalizes insulin responsiveness in chow-fed mice lacking hepatocyte Jak2. A and B: Total body weight and
fat mass in CON, JAK2L, and JAK2LA mice. C: Percent body fat as a fraction of total body weight. D and E: Percent epididymal visceral and
inguinal subcutaneous fat as a fraction of total body weight. F: Fed plasma FFAs. G and H: Fasting blood glucose and plasma insulin. I: ITT
expressed as a percentage of basal (fasting) glucose in CON, JAK2L, and JAK2LA mice. n = 7–19 mice/cohort. Data are mean 6 SEM. *P ,
0.05, **P , 0.01, ***P , 0.001, ****P , 0.0001 (for CON vs. JAK2L in I); ##P , 0.01, ####P , 0.0001 (for JAK2L vs. JAK2LA in I) by one-way
(A–H) or two-way (I) ANOVA.
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the chow-fed cohort, JAK2L mice were hyperglycemic (Fig.
4G) and hyperinsulinemic versus CON mice (Fig. 4H). De-
spite having similar fasting glucose levels, JAK2LA mice
were hypoinsulinemic compared with CON mice (Fig. 4H).
Consistent with this finding, JAK2LA mice were hyperre-
sponsive to insulin during ITT (Fig. 4I).
HFD-Fed JAK2LA Mice Retain Hepatic Insulin Sensitivity
We next performed hyperinsulinemic-euglycemic clamps to
definitively determine tissue-specific insulin sensitivity
in the HFD-challenged mice. Plasma insulin (Supplementary
Fig. 1C) and glucose levels (Fig. 5A) were matched during
steady state in response to a fixed- and variable-rate infu-
sion of each, respectively, during the clamp. At steady-state
euglycemia, the GIR in JAK2LA mice was 222% greater
than CON levels (Fig. 5B and C). Conversely, JAK2L mice
required ;65% lower GIR than CON mice. Although basal
EGP did not statistically differ among groups (Fig. 5D),
no suppression of EGP occurred after insulin infusion
in JAK2L mice (Fig. 5E and F). On the other hand, insu-
lin fully suppressed EGP in clamped JAK2LA animals,
and this was statistically greater than in both JAK2L
Figure 2—Loss of hepatocyte Jak2 induces hepatic insulin resistance in chow-fed mice in an adipocyte Jak2–dependent manner. A and B:
Blood glucose levels and GIR during glucose infusion to achieve euglycemia in CON, JAK2L, and JAK2LA mice. C: GIR at euglycemia. D and E:
Basal and clamped EGP. F: Percent suppression of EGP after insulin infusion. G: Whole-body glucose uptake. H and I: Tissue-specific glucose
uptake in gastrocnemius and epididymal visceral fat. J and K: Basal and clamped plasma FFA levels. L: Percent suppression of plasma FFA after
insulin infusion. n = 8–9mice/cohort. Data are mean6 SEM. A: **P, 0.01, ****P, 0.0001 (CON vs. JAK2L) and #P, 0.5, ###P, 0.001, ####P,
0.0001 (JAK2L vs. JAK2LA) by two-way ANOVA. B: ***P , 0.001, ****P , 0.0001 for both CON vs. JAK2L and JAK2L vs. JAK2LA by two-way
ANOVA. C–L: *P , 0.05, **P , 0.01, ***P , 0.001, **** P , 0.0001 by one-way ANOVA. 2-DG, 2-deoxy-D-glucose.
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and CON mice (Fig. 5E and F). Whole-body glucose dis-
posal (Fig. 5G) as well as skeletal muscle (Fig. 5H) and
adipose tissue glucose uptake (Fig. 5I) were increased in
JAK2LA mice. Neither whole-body glucose disposal
(Fig. 5G) nor skeletal muscle glucose uptake (Fig. 5H) dif-
fered between CON and JAK2L mice, whereas adipose tis-
sue glucose uptake was reduced in JAK2L mice (Fig. 5I).
Therefore, loss of hepatocyte Jak2 abrogates insulin sensi-
tivity almost entirely through inhibition of insulin-
mediated suppression of EGP. Concomitant disruption
of adipocyte Jak2 confers protection from whole-body and
hepatic insulin resistance compared with CON and JAK2L
mice.
As opposed to effects on basal EGP, overnight fasted,
basal FFA levels in HFD-fed JAK2LA mice were decreased
(Fig. 5J). After insulin infusion, plasma FFA levels (Fig. 5K)
were suppressed by ;46%, 27%, and 52% in the CON,
JAK2L, and JAK2LA mice, respectively, although these dis-
parities were not significant (Fig. 5L). In contrast to chow
data where there were no differences in plasma FFA levels
under clamped conditions (Fig. 2K), plasma FFA levels were
markedly lower in JAK2LA mice than in CON and JAK2L
Figure 3—Hepatic lipids in chow-fed mice. Heat map and hierarchical clustering of lipidomics results from the livers of chow-fed CON, JAK2L,
and JAK2LA mice showing TAG species (A), DAG species (B), CE species (C), and CER species (D). n = 5/cohort.
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mice, which were not different (Fig. 5K). Therefore, although
reduced plasma FFAs and improved hepatic insulin sensi-
tivity in HFD-fed JAK2LA mice were consistent with the
concept that lipolysis regulates hepatic glucose production,
the lack of difference in plasma FFAs between CON and
JAK2L mice despite clear differences in clamped rates of
hepatic glucose production did not (Fig. 5E and K). As in
chow-fed mice, differences in circulating FFA levels did not
correlate with divergences in hepatic insulin sensitivity.
Loss of Adipocyte JAK2 Confers Hepatic Insulin
Sensitivity in the Face of Fatty Liver
After HFD, total hepatic TAG (Fig. 6A), CE (Fig. 6C), and
CER (Fig. 6D) levels were highest in the JAK2LA cohort.
Total DAG levels were highest in JAK2L liver, with levels in
JAK2LA liver intermediate to CON liver. However, individ-
ual species also were elevated in JAK2LA versus CON liver
(Fig. 6B). Therefore, although loss of adipocyte Jak2 is epi-
static to liver JAK2 in terms of hepatic insulin sensitivity,
compound adipocyte-hepatocyte Jak2 deletion did not pre-
vent HFD-induced fatty liver.
Loss of Hepatocyte Jak2 Induces Hepatic Insulin
Resistance Independent of Altered Liver Insulin
Signaling
To determine how hepatic insulin resistance occurs in an
adipocyte Jak2–dependent manner, we assessed signaling in
insulin-responsive tissues of HFD-fed mice at the end of
hyperinsulinemic-euglycemic clamps. Despite profound phys-
iological hepatic insulin resistance, levels of neither phos-
phorylated (serine 473, pAKT) AKT nor phosphorylated
PRAS40 (threonine 246, pPRAS40) were attenuated in livers
of clamped JAK2L mice (Fig. 7A–C). To determine whether
livers of clamped mice were exposed to sufficient insulin
to adequately assess hepatic insulin signaling, we compared
pAKT in the fasted (basal) state with that of clamped
tissue. Although levels of pAKT were increased on average
by .300%, these results were not significant (Supplemen-
tary Fig. 2). Basal levels of pAKT were higher in JAK2L and
JAK2LA livers, and no induction with insulin (clamped
samples) was found. Therefore, we cannot exclude the pos-
sibility that our clamp studies might preferentially high-
light the indirect (e.g., adipocyte) effects of hepatic insulin
Figure 4—JAK2LA mice maintain exquisite insulin responsiveness after dietary challenge. A and B: Total body weight and fat mass in CON,
JAK2L, and JAK2LA HFD-fed mice. C: Percent body fat as a fraction of total body weight. D and E: Percent epididymal visceral and inguinal
subcutaneous fat as a fraction of total body weight. F: Fed plasma FFAs. G and H: Fasting blood glucose and plasma insulin. I: ITT expressed as
a percentage of basal (fasting) glucose in CON, JAK2L, and JAK2LA mice. n = 7–17/cohort. Data are mean6 SEM. *P, 0.05, **P, 0.01, ***P,
0.001, ****P , 0.0001 (for CON vs. JAK2LA in I); ####P , 0.0001 (for JAK2L vs. JAK2LA in I); $$P , 0.01 (for CON vs. JAK2L in I) by one-way
(A–H) or two-way (I) ANOVA.
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sensitivity regulation. In other insulin sensitive tissues, such
as skeletal muscle and epididymal adipose tissue (Fig. 7D–F),
pAKT and pPRAS40 were augmented in JAK2LA mice,
consistent with the glucose uptake data from HFD-fed
clamped mice (Fig. 5H and I). Of note, adipose tissue pAKT
levels were attenuated in mice lacking hepatocyte Jak2, and
this was entirely reversed by concomitant deletion of
adipocyte Jak2 (Fig. 7G–I). Therefore, insulin resistance
in JAK2L mice is associated with disruption of adipose tis-
sue insulin signaling in an adipocyte JAK2–dependent
manner.
JAK2LA Mice Uncouple Liver Fat and Adiposity From
Insulin Sensitivity
Given the strong positive correlations between steatosis and
adiposity with insulin resistance, we examined these param-
eters against whole-body and hepatic insulin sensitivity in
JAK2L and JAK2LA mice. As expected, whole-body insulin
sensitivity, as measured by GIR, fell precipitously when CON
mice were fed HFD, which was associated with increased liver
TGs (Fig. 8A) and percent body fat (Fig. 8B). The same trend
was observed for JAK2L mice. Conversely, increased liver
TG and body fat after HFD were coincident with augmented
Figure 5—Loss of adipocyte Jak2 imparts hepatic and whole-body insulin sensitivity in HFD-fed mice on the JAK2L background. A and B: Blood
glucose levels and GIR during glucose infusion to achieve euglycemia in CON, JAK2L, and JAK2LA mice. C: GIR at euglycemia. D and E: Basal
and clamped EGP. F: Percent suppression of EGP after insulin infusion. G: Whole-body glucose uptake. H and I: Tissue-specific glucose uptake
in gastrocnemius and epididymal visceral fat. J and K: Basal and clamped plasma FFA levels. L: Percent suppression of plasma FFA after insulin
infusion. n = 6–10/cohort. Data are mean 6 SEM. *P , 0.05, **P , 0.01, ***P , 0.001, ****P , 0.0001 (for CON vs. JAK2LA in A and B); #P ,
0.05, ##P , 0.01, ####P , 0.0001 (for JAK2L vs. JAK2LA in A and B); $P , 0.05 (for CON vs. JAK2L in A) by two-way (A and B) or one-way
(C–L) ANOVA.
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insulin sensitivity in JAK2LA animals. Similar patterns were
observed for hepatic insulin sensitivity such that attenuated
EGP in CON and JAK2L mice was concurrent with in-
creased hepatic lipid content (Fig. 8C) and adiposity (Fig.
8D). As opposed to these anticipated associations seen in
these cohorts, steatosis and increased body fat were associ-
ated with augmented hepatic insulin sensitivity in JAK2LA
animals. Therefore, JAK2LA mice uncouple the prevalent cor-
relations of hepatic lipid content and adiposity from insulin
resistance.
We previously showed that JAK2LA mice have impaired
lipolysis, which negatively correlates with insulin sen-
sitivity (6). Therefore, we reasoned that insulin-mediated
suppression of circulating FFA, a surrogate marker of lipol-
ysis, would correlate with EGP. In chow-fed CON mice, EGP
was reduced ;60% after the clamp, whereas insulin-medi-
ated suppression of FFA was also reduced ;60% (Supple-
mentary Fig. 3A). The near-complete hepatic insulin
resistance in clamped JAK2L mice was associated with an
;50% reduction in the ability of insulin to reduce circulating
Figure 6—JAK2LA mice develop fatty liver after an HFD. Heat map and hierarchical clustering of lipidomics results from livers of HFD-fed CON,
JAK2L, and JAK2LA mice showing TAG species (A), DAG species (B), CE species (C), and CER species (D). n = 5/cohort.
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FFA, consistent with a role for FFA in insulin resistance.
However, the maintenance of insulin sensitivity in clamped,
chow-fed JAK2LA mice was associated with a reduction in
insulin-mediated suppression of plasma FFA (CON 56%,
JAK2LA 25%). A similar pattern was noted for HFD-fed
mice (Supplementary Fig. 3B) such that augmented hepatic
insulin sensitivity in clamped JAK2LA mice was not associ-
ated with an increase in insulin-mediated reductions in
circulating FFA (CON 54%, JAK2LA 55%). Therefore, aug-
mented insulin sensitivity in JAK2LA mice is dissociated
from fatty liver, adiposity, and insulin-mediated suppression
of lipolysis.
Figure 7—JAK2L mice have normal liver insulin signaling despite hepatic insulin resistance. Liver (A–C), gastrocnemius (D–F), and epididymal
(G–I) adipose tissues were collected at the end of the clamp from CON, JAK2L, and JAK2LA HFD-fed mice (Fig. 5). Tissues were lysed and
analyzed for phosphorylated AKT (pAKT) and PRAS40 (pPRAS40) as well as for total AKT and PRAS40 by Western blot. Fluorescent LiCor
images were used to quantify phosphorylated:total protein ratios. n = 4/cohort. Data are mean 6 SEM. *P , 0.05, **P , 0.01, ***P , 0.001 by
one-way ANOVA. A.U., arbitrary unit.
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DISCUSSION
Excess GH has been proposed to be both a cause and a potential
treatment for systemic metabolic disease (25). Recombinant
GH has ostensible metabolic benefits and has been put for-
ward as a treatment option for diabetes (26). Also confusing
the matter around the potential effects of targeting GH for
metabolic disease is the vast array of phenotypes associated
with loss-of-function GH signaling. In particular, although
congenital GHI reduces the lifelong risk of developing di-
abetes (27), adult-onset GHD is characterized by insulin
resistance (28). The mechanisms that drive these dispa-
rate findings are unknown. We present data demonstrat-
ing that JAK2, an obligate transducer of GH and other
cytokine signals, regulates metabolic homeostasis in a tissue-
specific manner. Specifically, hepatocyte-specific Jak2 disrup-
tion promotes hepatic and whole-body insulin resistance,
hepatic lipid deposition, resistance to diet-induced obesity,
and attenuation of adipose tissue AKT activity. Concomi-
tant loss of adipocyte JAK2 reverses these phenotypes on
chow diet. Therefore, adipocyte Jak2 is epistatic to hepato-
cyte Jak2 under chow-fed conditions. However, when chal-
lenged with excess dietary lipid, loss of adipocyte JAK2 is
unable to overcome the hepatocyte-autonomous effects and
resultant hepatic lipid deposition and fails to prevent diet-
induced obesity. Regardless, deleting adipocyte Jak2 is suf-
ficient to maintain and augment insulin sensitivity, even in
the face of fatty liver. Of note, however, disrupting adipo-
cyte Jak2 is sufficient to maintain and augment insulin
sensitivity, even in the face of fatty liver and adiposity.
Previously, we showed that net in vivo lipolysis was
increased in JAK2L mice and decreased in JAK2LA mice (6).
Furthermore, systemic GH treatment indirectly promotes
Figure 8—JAK2LA mice uncouple fatty liver and adiposity from insulin resistance. GIR at the end of the clamp plotted against total liver TGs (A)
and percent body fat (B) for CON, JAK2L, and JAK2LA mice fed chow or HFD. Percent suppression of EGP at the end of the clamp plotted
against total liver TGs (C) and percent body fat (D). Plotted are the GIR and EGP at the end of the clamp experiments reported in Figs. 2 (chow)
and 5 (HFD), and the means of percent body fat determined from experiments reported in Figs. 1 (chow) and 4 (HFD). Total liver TGs were
determined from livers collected from mice used for experiments 1 (chow) and 4 (HFD). n = 5–8/cohort. Data are mean 6 SEM.
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lipolysis by inhibiting insulin-mediated suppression of lipol-
ysis in an adipocyte Jak2–dependent manner (7). Consis-
tent with these data, the current findings did not reveal the
same magnitude in reductions in plasma FFA in clamped
JAK2L mice compared with CON mice. However, increased
hepatic insulin sensitivity in JAK2LA mice did not correlate
with augmented insulin-mediated suppression of FFA (Sup-
plementary Fig. 3). Given that circulating FFA levels reflect
the balance of tissue release and uptake, the reduced levels of
fasting plasma FFA in hyperinsulinemic-euglycemic clamped
JAK2L and JAK2LAmice may reflect increased hepatic uptake.
Consistent with the finding that GH signaling suppresses
hepatocyte Cd36 expression (15), we found that JAK2LA
livers have;20-fold increased levels of Cd36 (Supplementary
Fig. 1D). We previously showed that either hepatic deletion
of Cd36 or loss of adipocyte Jak2 prevents fatty liver de-
velopment in chow-fed JAK2L mice (6,15). Collectively, the
data support a mechanism whereby hepatocyte-specific GHI
drives increased secretion of GH, which in turn induces
adipocyte pathway hyperactivation and attenuation of insulin-
mediated inhibition of lipolysis. Subsequently, circulating by-
products of adipocyte lipolysis are taken up by hepatocytes
in a CD36-dependent manner and promote lipid deposition.
The role of hepatocyte-autonomous insulin signaling in
suppressing hepatic glucose output is not clear. Historically,
whether insulin-mediated hepatic insulin sensitivity is
controlled directly in hepatocytes, indirectly in peripheral
tissues, or both has been debated. Elegant experiments from
the 1950s to 1990s showed that insulin-mediated suppression
of hepatic glucose output is likely controlled by peripheral
(indirect) as much as direct hepatic insulin signaling (29).
With the publication of the liver insulin receptor knockout
mouse, opinion shifted toward the notion that the predom-
inant regulation of hepatic glucose output was through di-
rect insulin signaling in the hepatocyte (30). More recently,
clamp studies seemed to indicate that insulin acts directly
on the liver to suppress hepatic glucose production (20).
However, genetic studies also have shown that hepatic in-
sulin signaling is dispensable for suppression of EGP (21).
The extrahepatic mechanism responsible for hepatic insulin
sensitivity has been proposed to be adipose tissue lipolysis
(8,31). This is consistent with the current recent findings
demonstrating that adipose tissue mediates GH-induced
hepatic insulin resistance, which correlates with reduc-
tions in lipolysis (7). Furthermore, inhibition of lipolysis in
GH-treated humans restores insulin sensitivity (9,10). The
current experiments support the existence of an extrahe-
patic mechanism in the regulation of hepatic glucose pro-
duction. In addition, a defect in AKT activation exists in the
adipose tissue of JAK2L mice that is corrected by concom-
itant disruption of adipocyte Jak2, which correlates with
augmented physiological hepatic insulin sensitivity.
The current results also demonstrate that chronic adipose
tissue exposure to elevated GH, as occurs in JAK2L animals,
can interfere with insulin responsiveness at the level of
AKT activation. Phosphorylation of PRAS40 threonine 246
by activated AKT relieves the ability of PRAS40 to inhibit
mTORC1 (19). Given the reduced levels of adipose tissue
phosphorylation of PRAS40 threonine 246 in JAK2L mice,
mTORC1 activity may be attenuated. Of note, adipocyte
mTORC1 mediates adiposity, hepatic lipid deposition, and
systemic insulin sensitivity (32) similar to adipocyte Jak2
(7). It will be paramount to determine whether mTORC1 is
involved in GH-mediated adipocyte physiology.
Insulin sensitivity negatively correlates with hepatic and
whole-body lipid content (33,34). However, as we observed
here, steatosis and adiposity have been dissociated from
insulin resistance (27,35,36). The mechanism behind the
uncoupling of insulin resistance from hepatic lipid accumu-
lation is unknown. Examples exist of nonalcoholic fatty liver
disease (NAFLD) and NASH being uncoupled from insulin
resistance. For instance, knockdown on CGI-58 promotes
steatosis yet protects from HFD-associated hepatic insulin
resistance (35). Moreover, genetic variants of PNPLA3 and
TM6SF2 predispose to NASH but not to diabetes and are
associated with a higher sensitivity of insulin to inhibit
lipolysis (36). Circulating FFAs, but not hepatic TGs, have
been reported to be associated with NAFLD (37). The rate
of lipolysis, which produces FFA, is increased in the setting
of fatty liver (38,39), suggesting that adipose tissue may
regulate pathological NAFLD (40). Indeed, removal of epi-
didymal white adipose tissue attenuates the development of
fatty and fibrotic liver (41). Collectively, data support the
hypothesis that adipose tissue, possibly through lipolysis,
regulates some metabolic consequences in liver (41,42).
Uncovering the fates of the fatty livers observed here to
determine whether retaining hepatic insulin sensitivity in
JAK2LA mice influences the ultimate metabolic and path-
ological outcomes would be interesting.
Our studies have potential limitations that merit comment.
First, this work shows, by using gold-standard techniques, that
hepatocyte-specific disruption of Jak2 (JAK2L) leads to se-
vere whole-body and hepatic insulin resistance. However, it
is important to consider the differences in body weight and
composition between genotypes and the impact on how
assessments of glucose homeostasis are performed and nor-
malized. We previously published quantitative magnetic
resonance data that reported reductions in lean mass in
both JAK2L and JAK2LA mice, which occurs without alter-
ations in food intake, energy expenditure, or ambulatory
activity (6). During a hyperinsulinemic-euglycemic clamp,
both the dosing of insulin and the normalization of the
glucose turnover measurements are typically based on
body weight. In obese models, where increases in body weight
primarily are due to changes in fat mass, this can result in the
inadvertent overdosing of insulin and underestimation of glu-
cose turnover relative to lean mass, as previously discussed
(23,43). Of note, in the current studies, plasma insulin
values were matched across genotypes during both the
chow and the HFD clamps. Furthermore, although normal-
izing the glucose turnover data to lean mass or per mouse
modestly affected the magnitude of the reported differences
in some cases, there was no effect on the significance of any
of the differences we detected when normalized per kilogram
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body weight. Thus, although differences in body weight and fat
mass existed between some groups in our studies, the differ-
ences did not affect the overall interpretation of the results.
Second, it is important to allow that JAK2 is well known
to transduce signals downstream of multiple cytokines other
that GH, such as leptin and interleukin-6. As such, although
from these and prior experiments we can say definitively that
we have abrogated GH signaling, we will need to conduct more-
definitive experiments, such as adipocyte-specific deletion
of the Ghr, to determine whether the phenotypes presented
here are entirely attributed to loss of GH signaling.
In summary, concomitant disruption of adipocyte Jak2
(JAK2LA) corrects both the steatosis and the insulin resis-
tance associated with hepatocyte-only Jak2 deletion (JAK2L),
implicating increased liver lipid as the driver of systemic
metabolic abnormalities. However, in the cohort of HFD-
fed animals, although JAK2L mice were steatotic and in-
sulin resistant (despite marked reductions in body fat),
JAK2LA animals were even more steatotic and yet retained
exquisite whole-body and hepatic insulin sensitivity. This
strongly suggests that at least on this diet, the liver lipid
does not drive the systemic metabolic abnormalities and, in-
stead, that hepatic insulin sensitivity is controlled by adipocyte
Jak2 and correlates with augmented insulin-mediated
suppression of FFA. Finally, we show that physiological
hepatic insulin resistance is associated with attenuated ad-
ipose tissue AKT activity in an adipocyte Jak2–dependent
manner.
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